Anticholinergic Exposure during Rehabilitation

Cognitive and Physical Function Outcomes in Patients with Delirium Superimposed on Dementia

Ann Kolanowski, Jacqueline Mogle, Donna M. Fick, Noll Campbell, Nikki Hill, Paula Mulhall, Liza Behrens, Elise Colancecco, Malaz Boustani, Linda Clare

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives We examined the association between anticholinergic medication exposure and subsequent cognitive and physical function in patients with delirium superimposed on dementia during rehabilitation. We also examined length of stay and discharge disposition by anticholinergic medication exposure. Design In this secondary analysis we used control group data from an ongoing randomized clinical trial. Setting/Participants Participants with delirium and dementia were enrolled at admission to post-acute care. These 99 participants had a mean age of 86.11 (±6.83) years; 67.6% were women; 98% were Caucasian; and 33% were positive for at least one APOE e4 allele. Measures We obtained daily measures of cognitive and physical function using: Digit Span; memory, orientation and attention items from the Montreal Cognitive Assessment; CLOX; the Confusion Assessment Method; and the Barthel Index. Anticholinergic medication exposure was measured weekly using the Anticholinergic Cognitive Burden Scale. Results Using multilevel models for time we found that greater use of clinically relevant anticholinergic medications in the previous week reduced cognitive and physical function, as measured by Digit Span Backwards and the Barthel index, in the current week. There was no effect of anticholinergic medication use on delirium severity, and APOE status did not moderate any outcomes. Greater use of clinically relevant anticholinergic medications was related to longer length of stay but not discharge disposition. Conclusions For vulnerable older adults, anticholinergic exposure represents a potentially modifiable risk factor for poor attention, working memory, physical function, and greater length of stay during rehabilitation.

Original languageEnglish (US)
Pages (from-to)1250-1258
Number of pages9
JournalAmerican Journal of Geriatric Psychiatry
Volume23
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Delirium
Cholinergic Antagonists
Cognition
Dementia
Rehabilitation
Length of Stay
Subacute Care
Confusion
Short-Term Memory
Randomized Controlled Trials
Alleles
Control Groups

Keywords

  • Anticholinergic exposure
  • cognition
  • dementia
  • physical function
  • post-acute care

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology

Cite this

Anticholinergic Exposure during Rehabilitation : Cognitive and Physical Function Outcomes in Patients with Delirium Superimposed on Dementia. / Kolanowski, Ann; Mogle, Jacqueline; Fick, Donna M.; Campbell, Noll; Hill, Nikki; Mulhall, Paula; Behrens, Liza; Colancecco, Elise; Boustani, Malaz; Clare, Linda.

In: American Journal of Geriatric Psychiatry, Vol. 23, No. 12, 01.12.2015, p. 1250-1258.

Research output: Contribution to journalArticle

Kolanowski, Ann ; Mogle, Jacqueline ; Fick, Donna M. ; Campbell, Noll ; Hill, Nikki ; Mulhall, Paula ; Behrens, Liza ; Colancecco, Elise ; Boustani, Malaz ; Clare, Linda. / Anticholinergic Exposure during Rehabilitation : Cognitive and Physical Function Outcomes in Patients with Delirium Superimposed on Dementia. In: American Journal of Geriatric Psychiatry. 2015 ; Vol. 23, No. 12. pp. 1250-1258.
@article{c672a6b33a344980b3edf5f1fc89ac9c,
title = "Anticholinergic Exposure during Rehabilitation: Cognitive and Physical Function Outcomes in Patients with Delirium Superimposed on Dementia",
abstract = "Objectives We examined the association between anticholinergic medication exposure and subsequent cognitive and physical function in patients with delirium superimposed on dementia during rehabilitation. We also examined length of stay and discharge disposition by anticholinergic medication exposure. Design In this secondary analysis we used control group data from an ongoing randomized clinical trial. Setting/Participants Participants with delirium and dementia were enrolled at admission to post-acute care. These 99 participants had a mean age of 86.11 (±6.83) years; 67.6{\%} were women; 98{\%} were Caucasian; and 33{\%} were positive for at least one APOE e4 allele. Measures We obtained daily measures of cognitive and physical function using: Digit Span; memory, orientation and attention items from the Montreal Cognitive Assessment; CLOX; the Confusion Assessment Method; and the Barthel Index. Anticholinergic medication exposure was measured weekly using the Anticholinergic Cognitive Burden Scale. Results Using multilevel models for time we found that greater use of clinically relevant anticholinergic medications in the previous week reduced cognitive and physical function, as measured by Digit Span Backwards and the Barthel index, in the current week. There was no effect of anticholinergic medication use on delirium severity, and APOE status did not moderate any outcomes. Greater use of clinically relevant anticholinergic medications was related to longer length of stay but not discharge disposition. Conclusions For vulnerable older adults, anticholinergic exposure represents a potentially modifiable risk factor for poor attention, working memory, physical function, and greater length of stay during rehabilitation.",
keywords = "Anticholinergic exposure, cognition, dementia, physical function, post-acute care",
author = "Ann Kolanowski and Jacqueline Mogle and Fick, {Donna M.} and Noll Campbell and Nikki Hill and Paula Mulhall and Liza Behrens and Elise Colancecco and Malaz Boustani and Linda Clare",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.jagp.2015.07.004",
language = "English (US)",
volume = "23",
pages = "1250--1258",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Anticholinergic Exposure during Rehabilitation

T2 - Cognitive and Physical Function Outcomes in Patients with Delirium Superimposed on Dementia

AU - Kolanowski, Ann

AU - Mogle, Jacqueline

AU - Fick, Donna M.

AU - Campbell, Noll

AU - Hill, Nikki

AU - Mulhall, Paula

AU - Behrens, Liza

AU - Colancecco, Elise

AU - Boustani, Malaz

AU - Clare, Linda

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objectives We examined the association between anticholinergic medication exposure and subsequent cognitive and physical function in patients with delirium superimposed on dementia during rehabilitation. We also examined length of stay and discharge disposition by anticholinergic medication exposure. Design In this secondary analysis we used control group data from an ongoing randomized clinical trial. Setting/Participants Participants with delirium and dementia were enrolled at admission to post-acute care. These 99 participants had a mean age of 86.11 (±6.83) years; 67.6% were women; 98% were Caucasian; and 33% were positive for at least one APOE e4 allele. Measures We obtained daily measures of cognitive and physical function using: Digit Span; memory, orientation and attention items from the Montreal Cognitive Assessment; CLOX; the Confusion Assessment Method; and the Barthel Index. Anticholinergic medication exposure was measured weekly using the Anticholinergic Cognitive Burden Scale. Results Using multilevel models for time we found that greater use of clinically relevant anticholinergic medications in the previous week reduced cognitive and physical function, as measured by Digit Span Backwards and the Barthel index, in the current week. There was no effect of anticholinergic medication use on delirium severity, and APOE status did not moderate any outcomes. Greater use of clinically relevant anticholinergic medications was related to longer length of stay but not discharge disposition. Conclusions For vulnerable older adults, anticholinergic exposure represents a potentially modifiable risk factor for poor attention, working memory, physical function, and greater length of stay during rehabilitation.

AB - Objectives We examined the association between anticholinergic medication exposure and subsequent cognitive and physical function in patients with delirium superimposed on dementia during rehabilitation. We also examined length of stay and discharge disposition by anticholinergic medication exposure. Design In this secondary analysis we used control group data from an ongoing randomized clinical trial. Setting/Participants Participants with delirium and dementia were enrolled at admission to post-acute care. These 99 participants had a mean age of 86.11 (±6.83) years; 67.6% were women; 98% were Caucasian; and 33% were positive for at least one APOE e4 allele. Measures We obtained daily measures of cognitive and physical function using: Digit Span; memory, orientation and attention items from the Montreal Cognitive Assessment; CLOX; the Confusion Assessment Method; and the Barthel Index. Anticholinergic medication exposure was measured weekly using the Anticholinergic Cognitive Burden Scale. Results Using multilevel models for time we found that greater use of clinically relevant anticholinergic medications in the previous week reduced cognitive and physical function, as measured by Digit Span Backwards and the Barthel index, in the current week. There was no effect of anticholinergic medication use on delirium severity, and APOE status did not moderate any outcomes. Greater use of clinically relevant anticholinergic medications was related to longer length of stay but not discharge disposition. Conclusions For vulnerable older adults, anticholinergic exposure represents a potentially modifiable risk factor for poor attention, working memory, physical function, and greater length of stay during rehabilitation.

KW - Anticholinergic exposure

KW - cognition

KW - dementia

KW - physical function

KW - post-acute care

UR - http://www.scopus.com/inward/record.url?scp=84975882084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975882084&partnerID=8YFLogxK

U2 - 10.1016/j.jagp.2015.07.004

DO - 10.1016/j.jagp.2015.07.004

M3 - Article

VL - 23

SP - 1250

EP - 1258

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 12

ER -